Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) Director Steven Rubin purchased 10,000 shares of Entera Bio stock in a transaction dated Monday, February 9th. The shares were bought at an average price of $1.20 per share, for a total transaction of $12,000.00. Following the acquisition, the director owned 10,000 shares in the company, valued at approximately $12,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Entera Bio Trading Up 13.1%
Entera Bio stock opened at $1.64 on Thursday. The company has a 50-day moving average price of $1.70 and a 200 day moving average price of $2.03. Entera Bio Ltd. has a 12-month low of $1.00 and a 12-month high of $3.22. The stock has a market cap of $75.21 million, a P/E ratio of -6.56 and a beta of 1.84.
Entera Bio (NASDAQ:ENTX - Get Free Report) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.02. As a group, analysts forecast that Entera Bio Ltd. will post -0.28 EPS for the current year.
Hedge Funds Weigh In On Entera Bio
A number of hedge funds and other institutional investors have recently bought and sold shares of ENTX. Citadel Advisors LLC grew its position in Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company's stock valued at $77,000 after acquiring an additional 28,322 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of Entera Bio by 137.8% in the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company's stock valued at $84,000 after purchasing an additional 25,000 shares during the period. Finally, Bessemer Group Inc. purchased a new position in shares of Entera Bio in the second quarter valued at approximately $268,000. 14.11% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Entera Bio in a report on Monday. Wall Street Zen raised shares of Entera Bio to a "sell" rating in a research note on Saturday, December 27th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Entera Bio in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Entera Bio currently has a consensus rating of "Hold" and an average target price of $10.00.
Check Out Our Latest Stock Analysis on Entera Bio
Entera Bio Company Profile
(
Get Free Report)
Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.
The company's lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
